Skip to main content
EQ
NASDAQ Life Sciences

President and CSO Stephen Connelly Sells $723K in Company Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$2.94
Mkt Cap
$185.886M
52W Low
$0.27
52W High
$3.45
52W Position info
989% above low
Off High info
15% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

EQ has more than doubled off its 52-week low of $0.27.

Summary

Equillium's President and CSO, Stephen Connelly, sold $723,830 worth of common stock in open market transactions, following a recent Form 144 filing and contributing to a trend of insider selling.


Key Events · Ownership and Investor Activity · EQ

  • Key Insider Sells Significant Stake

    Stephen Connelly, President and CSO, sold 230,975 shares of common stock for a total value of $723,830 across two transactions on June 4-5, 2026.

  • Follows Intent to Sell Filing

    This Form 4 filing finalizes the sale previously indicated by a Form 144 filed on June 4, 2026, where Connelly declared his intent to sell over $632,000 worth of stock.

  • Substantial Reduction in Holdings

    The sale represents approximately 23% of Connelly's direct holdings prior to the transaction, leaving him with 762,025 shares post-sale.

  • Contributes to Insider Distribution Trend

    This transaction adds to a net insider distribution of over $1.45 million in open-market sales over the past 90 days, with no reported open-market purchases.


Analysis · EQ · Life Sciences

Equillium's President and CSO, Stephen Connelly, executed a significant open-market sale of common stock totaling over $723,000. This transaction follows a Form 144 filing just yesterday, indicating his intent to sell, and represents a substantial reduction in his direct holdings. The sale contributes to a broader pattern of insider distribution at the company, with over $1.45 million in net insider sales over the last 90 days, which could be viewed negatively by investors, especially following recent capital raises and a reverse stock split approval.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EQ was trading at $2.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $185.9M. The 52-week trading range was $0.27 to $3.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EQ - Latest Insights

EQ
Nov 12, 2026, 4:20 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $1.27 info
Change: -$0.070 (-5%) info
Market Cap: $106.199M info
EQ
Oct 26, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.29
Real-time Price: $1.27 info
Change: -$0.020 (-2%) info
Market Cap: $106.199M info
EQ
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $1.27 info
Change: +$0.1497 (+13%) info
Market Cap: $106.199M info
EQ
Oct 05, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $1.27 info
Change: -$0.150 (-11%) info
Market Cap: $106.199M info
EQ
Oct 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.27 info
Change: -$0.240 (-16%) info
Market Cap: $106.199M info